Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres Gastrointestinal / Cáncer del Ano / Recursos de NCI
National Cancer Institute®
Ultima Vez Modificado: 1 de marzo del 2002
1
UI - 11872307
AU - Vordermark D; Koelbl O
TI -
In regard to Kapp et al.: experience with split-course external beam
irradiation +/- chemotherapy and integrated (192)Ir high-dose-rate
brachytherapy in the treatment of primary carcinomas of the anal canal.
IJROBP 2001;49:997--1005.
SO - Int J Radiat Oncol Biol Phys 2002 Feb 1;52(2):580-1
2
UI - 11852508
AU - Lorenzo-Zuniga Garcia V; Tor Aguilera J; Balana Quintero C; Rey-Joly
TI -
Barroso C
[Cutaneous Paget's disease and adenocarcinoma]
SO - An Med Interna 2001 Dec;18(12):659
3
UI - 11793263
AU - Zbar AP; Nishikawa H; BeerGabel M
TI -
Vertical rectus abdominis myocutaneous transposition flap for total
pelvic exenteration in recurrent vulvar carcinoma invading the anus.
SO - Tech Coloproctol 2001 Apr;5(1):66
AD - Kaplan Medical Center, Rehovot, 76100 Israel. apzbar@zahav.net.il
4
UI - 11588559
AU - Thornton SC; Hirshorn SA; Bradway M; Levien D
TI -
Correct visualization of the anal ring.
SO - J Clin Gastroenterol 2001 Oct;33(4):346
5
UI - 11824234
AU - Geile D; Osterholzer G; Muller J
TI -
[Precancerous conditions and neoplasms of the anal area]
SO - Kongressbd Dtsch Ges Chir Kongr 2001;118():141-6
AD - Proktologisches Institut Munchen-Ost, Chirurgische Privatklinik
Bogenhausen, Denninger Strasse 44, 81679 Munchen.
Classification of this lesions could be done concerning localisation and
histological type. Squamous cell carcinoma of the anal canal are the
most often to be found, but overall neoplasias in this region are very
seldom. The most important role in pathogenesis seems to play infection
with HPV viruses. Symptoms are in the beginning unspecific and similar
to other common proctological diseases. Proctological diagnostic
procedures are to be combined with cytological methods. Therapeutic
management depends on malignant potential of the lesions and contains
local excision, total operation and combined radiochemotherapy, which is
today considered standard therapy of squamous cell carcinoma of the anal
canal.
6
UI - 11824250
AU - Raulf F
TI -
[Benign tumors--surgical indication?]
SO - Kongressbd Dtsch Ges Chir Kongr 2001;118():218-20
AD - Abteilung Chirurgie II/Koloproktologie, Raphaelsklinik Munster,
Klosterstrasse 75, 48143 Munster.
Diagnostic and therapeutic options of the benign tumors in the anal
region will be discussed. There is no systematic scheme for these tumors
depending on the polymorph aspects and different matrices in the
borderline between ecto- and entoderma. Because of the localisation
either in perianal skin, fossa ischiorectalis or in the retrorectal
space there is a need of different therapeutic options and approaches.
7
UI - 11824363
AU - Jongen J; Reh M; Bock JU; Rabenhorst G
TI -
[Perianal precancerous conditions (Bowen disease, Paget disease,
Carcinoma in situ, Buschke-Lowenstein tumor)]
SO - Kongressbd Dtsch Ges Chir Kongr 2001;118():79-86
AD - Proktologische Praxis und Abteilung Chirurgische Proktologie,
Park-Klinik, Goethestrasse 11, 24116 Kiel.
Perianal premalignant lesions are rare. Any suspicious perianal lesion
or any perianal exanthema, that does not heal by non-surgical treatment
has to be biopsied for histology. Many premalignant lesions are
diagnosed as an incidental finding after anorectal surgery: any
anorectal specimen must be examined by the pathologist. Leukoplakia is a
facultative premalignant condition. High-grade anal intraepithelial
neoplasia (AIN) is an in situ squamous cell carcinoma, associated with
papillomavirus infection. Bowen's disease and Bowenoid papulosis are
clinical variations of high-grade AIN. Buschke-Lowenstein tumour (giant
condyloma) is a locally destructive tumour, that does not infiltrate or
cause metastases. Paget's disease is a premalignant lesion like AIN,
associated with other malignancies.
8
UI - 11713581
AU - Zucchini C; Biolchi A; Strippoli P; Solmi R; Rosati G; Del Governatore
TI -
M; Milano E; Ugolini G; Salfi N; Farina A; Caira A; Zanotti S; Carinci
P; Valvassori L
Expression profile of epidermal differentiation complex genes in normal
and anal cancer cells.
SO - Int J Oncol 2001 Dec;19(6):1133-41
AD - Institute of Histology and Embriology, Fondazione CARISBO Center for
Research into Molecular Genetics, Bologna, Italy.
Anal cancer originates from a peculiar histological region and provides
a useful model for investigating alterations in proliferation and/or
differentiation of neoplastic keratinocytes. Epidermal differentiation
complex (EDC) genes, which form one of the major gene clusters in the
human genome, are involved in the terminal differentiation of epithelial
cells and in many instances have been implicated in epithelial tumours.
We constructed a DNA macroarray capable of characterising the expression
profiles of the entire EDC gene complex in normal mucosa and anal cancer
biopsies of seven unrelated patients. Brain tissue and cultured
keratinocytes were used as controls. All anal cancer samples showed
expression profiles in which none of the EDC genes was silent, as
evaluated by phosphor-imager analysis. Variance analysis showed
significantly lower expression of SPRR2 with respect to SPRR1 or SPRR3,
and significantly higher expression of S100A8 than of other S100A
subfamily members. At hierarchical clustering analysis, the four
basaloid anal cancer cases conglomerated in the top five positions. The
macroarray method used by us provides the first demonstration of the
expression profile of the EDC gene family in anal cancer, and is capable
of producing significant information on the subgrouping of epithelial
tumours such as anal cancer.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Dr. Vapiwala discusses the public awareness of prostate cancer and the public support for the disease. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

